•
Jun 30, 2023
HCA Q2 2023 Earnings Report
HCA Healthcare's financial performance for Q2 2023 was reported, demonstrating growth in revenue and net income.
Key Takeaways
HCA Healthcare reported solid second-quarter results, driven by strong demand and effective execution, with revenues reaching $15.861 billion and net income attributable to HCA Healthcare, Inc. totaling $1.193 billion, or $4.29 per diluted share.
Revenues totaled $15.861 billion.
Net income attributable to HCA Healthcare, Inc. totaled $1.193 billion, or $4.29 per diluted share.
Adjusted EBITDA totaled $3.056 billion.
Cash flows from operating activities totaled $2.475 billion.
HCA
HCA
Forward Guidance
The 2023 guidance ranges for the year have been revised from our first quarter release.
Positive Outlook
- Revenues $63.25 to $64.75 billion
- Net Income Attributable to HCA Healthcare, Inc. $4.900 to $5.255 billion
- Adjusted EBITDA $12.3 to $12.8 billion
- EPS (diluted) $17.70 to $18.90 per diluted share
- Capital expenditures for 2023, excluding acquisitions, are estimated to be approximately $4.7 billion compared to $4.6 billion previously.
Challenges Ahead
- Changes in general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions
- Changes in revenues due to declining patient volumes
- Changes in payer mix (including increases in uninsured and underinsured patients)
- Potential increased expenses related to labor, supply chain or other expenditures
- Workforce disruptions and supply shortages and disruptions